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Anti-Inflammatory Effects of Quercetin on High-Glucose
and Pro-Inflammatory Cytokine Challenged Vascular
Endothelial Cell Metabolism
Besim Ozyel, Gwénaëlle Le Gall, Paul W. Needs, and Paul A. Kroon*
Scope: Pro-inflammatory stimuli such as hyperglycemia and cytokines have
been shown to negatively affect endothelial cell functions. The aim of this
study is to assess the potential of quercetin and its human metabolites to
overcome the deleterious effects of hyperglycemic or inflammatory conditions
on the vascular endothelium by modulating endothelial cell metabolism.
Methods and results: A metabolomics approach enabled identification and
quantification of 27 human umbilical vein endothelial cell (HUVEC)
metabolites. Treatment of HUVECs with high-glucose concentrations causes
significant increases in lactate and glutamate concentrations. Quercetin
inhibits glucose-induced increases in lactate and adenosine 5′-triphosphate
(ATP) and also increased inosine concentrations. Tumor necrosis factor
𝜶-treatment (TNF𝜶) of HUVECs causes increases in asparagine and
decreases in aspartate concentrations. Co-treatment with quercetin reduces
pyruvate concentrations compared to TNF𝜶-only treated controls.
Subsequently, it was shown that quercetin and its HUVEC phase-2 conjugates
inhibit adenosine deaminase, xanthine oxidase and 5′nucleotidase (CD73) but
not ectonucleoside triphosphate diphosphohydrolase-1 (CD39) or purine
nucleoside phosphorylase activities.
Conclusion: Quercetin was shown to alter the balance of HUVEC metabolites
towards a less inflamed phenotype, both alone and in the presence of
pro-inflammatory stimuli. These changes are consistent with the inhibition of
particular enzymes involved in purine metabolism by quercetin and its
HUVEC metabolites.
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1. Introduction
According toWorld Health Organization,
cardiovascular disease (CVD) is the lead-
ing cause of death globally.[1] The ma-
jor contributor to CVD is atherosclerosis,
and it is characterized as a chronic in-
flammatory disease.[2] Diabetes is known
to accelerate atherosclerosis however, the
mechanisms are not fully elucidated.[3]
Endothelial cells are responsible for
various important processes such as reg-
ulating vessel permeability, inflamma-
tion, and thrombosis.[4] Endothelial cell
dysfunction which leads to decreased
bioavailability of nitric oxide has an
impact on endothelial cell activation
where enhanced cell permeability, ele-
vated cell adhesion molecule expression
and reduced anti-thrombotic properties
are observed.[5] Therefore, endothelial
cell dysfunction and endothelial cell ac-
tivation concomitantly disrupt endothe-
lial cell function initiating atherosclerotic
plaque formation.[6]
High-glucose concentrations ex-
perienced during diabetes generate
inflammatory stimuli, which lead to en-
dothelial cell dysfunction and endothelial
cell activation. Reduced nitric oxide
production,[7] increased nuclear factor-kappaB (NF-кB)
activation,[8] increased cell adhesion molecule expression[9]
and expression of inflammatory genes[10] have been reported
when endothelial cells were exposed to hyperglycemic environ-
ment. There are also numerous reports providing evidence of the
anti-inflammatory[11] and anti-apoptotic[12] effects of polyphenols
when endothelial cells have been exposed to hyperglycemic and
pro-inflammatory conditions. To date, we are only aware of one
such report concerned with the effects of quercetin metabolites
on high-glucose treated vascular endothelial cells.[13] These
previous reports focused on targeted effects, particularly inflam-
mation responses and changes in gene expression and signaling.
Non-targeted approaches are useful for identifying a broad range
of effects and potentially unanticipated effects of changes in
conditions (e.g., glycemia, inflammation) on cell functions.
Evidence of links between changes in inflammation and cell
metabolism have emerged[14,15] and this directed us to use
non-targeted metabolomics approach to investigate the effects of
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high glucose and inflammatory cytokine treatments on cellular
metabolism.
Cultured endothelial cells are used to represent the vascular
endothelium. However, they are not homogenous which means
that endothelial cells from different vascular beds may behave
differently in response to various stimuli.[16] A previous study
revealed the heterogeneity of responses to pro-inflammatory
cytokines TNF𝛼, IL-1𝛽, and LPS by selected arterial and venous
endothelial cells where human umbilical vein endothelial cells
(HUVECs) developed comparatively strong inflammatory re-
sponses reflected as increased cell adhesionmolecule expression,
increased monocyte adhesion, and phosphorylation of signaling
molecules such as extracellular signal-regulated protein kinases
1 and 2 involved in inflammation.[17] In another study, glucose
transporters in arterial, venous, and capillary endothelial cells
were examined showing that HUVECs have similar glucose
transporter mRNA expression pattern and also comparable
protein levels of most abundantly found transporters, glucose
transporter 1 and 3, to these particular endothelial cells.[18]
Consequently, a HUVECmodel which has been extensively used
in diabetes and CVD research was employed in this study.[19]
The aim of the present study was to evaluate the ability
of quercetin and its phase-2 conjugates to overcome the pro-
inflammatory effects of hyperglycemia and cytokine treatments
in HUVECs. The data showed that quercetin and its conjugates
alter HUVEC energy metabolism, and we went on to provide ev-
idence that the observed changes in HUVEC energy metabolism
may be a consequence of direct interaction of quercetin and its
conjugates with the enzymes involved in purine metabolism.
2. Experimental Section
2.1. Cell Culture
HUVECs were obtained from Cambrex Bio Science (Woking-
ham, UK), and grown in endothelial cell basal growth medium
(EBM-2, 5.5 mm glucose) supplemented with fetal bovine serum,
nutrients, and growth factors (EGM-2 SingleQuots). HUVEC cul-
tures were maintained at 37 °C in an atmosphere at 5% CO2.
2.2. High-Glucose, TNF𝜶, and Polyphenol Challenge of HUVECs
After HUVECs reached confluence, culture medium was re-
placed with high-glucose medium (28.5 mm) for 18 h or medium
containing TNF𝛼 (10 ng mL−1) for 6 h. Polyphenol treatments
involved additional 2 h pre-treatment with quercetin (10 𝜇m)
followed by 18 h of high-glucose (28.5 mm) or 6 h of TNF𝛼
(10 ng mL−1) co-treatment.
2.3. Cell Quenching and Metabolite Extraction
First, a protocol that allowed quick arrest of cellular metabolism
and efficient extraction of metabolites using existing literature
methods as a starting point was optimized.[20,21] 80%HPLCgrade
methanol (−80 °C, 3ml) was used to quench the cells. After quick
removal of culture medium from the culture dish (10 cm2), cold
methanol was added. This was followed by 15 min incubation on
dry ice. A cell-scraper was used to detach the cells and disrupt
the cell membranes. The methanol solution containing HUVEC
metabolites was collected into a 5 mL centrifuge tube and cen-
trifuged (2000 g/ 5 min at 4 °C). The supernatant was saved and
pellet was re-constituted in 0.5 ml of 80%HPLC grademethanol.
Centrifugation step was repeated. The supernatants were pooled
and dried using a centrifugal evaporator.
2.4. Sample Preparation and NMR Acquisition
Dried intracellular extracts were re-constituted in a known
amount of buffer containing Na2HPO4, NaH2PO4, NaN3 and
TSP (sodium 3-(trimethylsilyl)-propionated4) inD2O. A 600MHz
Bruker Avance spectrometer fitted with a 5 mm TCI cryoprobe
and a 60 slot auto-sampler (Bruker, Germany) was used to acquire
high-resolution 1H NMR spectra with a 1D NOESY pulse se-
quence (NOESYPR1D). Samples were held at a constant temper-
ature of 26.85 °C. 2.05s acquisition involved 128 scans of 32768
complex data points, and the spectral width was 13.3 ppm. A low
power selective irradiation was applied at the water frequency to
suppress the residual water signal during the recycle delay (D1
= 2s) and mixing time (D8 = 0.10s). All spectra were phase- and
baseline-corrected manually using the TOPSPIN 2.0 software.
2.5. Hydrophilic Interaction Chromatography (HILIC) Mode
LC-MS/MS Analysis
Levels of adenosine 5′-triphosphate (ATP), adenosine 5′- diphos-
phate (ADP), adenosine 5′- monophosphate (AMP), adenosine,
inosine, and xanthine were measured in both intra- and ex-
tracellular samples. Prior to MS analysis, dried extracts were
dissolved in H2O. An Agilent 1200 HPLC system (Waldbronn,
Germany) coupled with an Applied Biosystems 4000 QTrap
triple quadrupole MS was employed using the analytical method
described by Preinerstorfer et al. (2010).[22] Analyst 1.5 software
(Applied Biosystems) was used to process data.
2.6. LC-DAD and LC-MS Analyses
Media samples were mixed using a bench top vortex, and cen-
trifuged at 13 000 rpm for 10 min at 4 °C using a bench top
centrifuge. Intracellular extracts were mixed using a bench top
vortex, and ultra-sonicated in a sonic water bath for 10 min and
then centrifuged at 13.000 rpm for 10 min at 4 °C. Supernatants
were analyzed with either LC-DAD or LC-MS.
Reverse phase HPLC analyses were conducted using an Ag-
ilent HP1100 system (Waldbronn) with ultraviolet diode array
detection. During chromatographic runs, autosampler temper-
ature was set to 4 °C, temperature of the column compartment
was 30 °C and injection volumes were between 20 and 100 𝜇L.
Metabolites were separated using a Phenomenex Luna 5-C18(2)
(250 × 4.60 mm, 5 𝜇m) column at a flow rate of 1 mL min−1.
Mobile phases were prepared as A) 50 mm ammonium acetate
in H2O (adjusted to pH 5) and B) 2% THF and 0.1% acetic acid
in acetonitrile. Gradient elution was detailed in the Supporting
Information.
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An Agilent 1100 HPLC system coupled with an Agilent
LC/MSD SL spectrometer was used for LC-MS analyses. The
same gradient elution was used for the LC-MS analyses. MS
in full scan in both positive and negative ion modes with elec-
trospray ionization was used to detect quercetin conjugates.
Individual standards for quercetin, isorhamnetin, rhamnetin,
tamarixetin, quercetin 3′-O-sulfate (Q3′-O-S), quercetin 3-
O-sulfate (Q3-O-S), quercetin 3′-glucuronide (Q3′-O-GlcA),
quercetin 3-glucuronide (Q3-O-GlcA), and isorhamnetin 3-
glucuronide (IsoR3-O-GlcA) were analyzed using LC-DAD and
LC-MS methods in order to help the metabolite identification
process and for quantification.
2.7. Enzymatic Assays
2.7.1. Adenosine Deaminase and Xanthine Oxidase
The effects of quercetin and its conjugates on adenosine deam-
inase (ADA) (recombinant human adenosine deaminase ex-
pressed in Escherichia coli) and xanthine oxidase (XO) (from
bovine milk) activity were tested using commercial enzymes
(Sigma-Aldrich) and the continuous spectrophotometric rate de-
termination assay procedures provided by the supplier.
Furthermore, ADA activity in HUVEC protein extracts was
tested. First, the confluent HUVECs were washed three-times
with PBS (room temperature) followed by the incubation on dry
ice for 15 min. Lysate was obtained by scraping the cells using a
cell scraper after addition of 400 𝜇L pure water and transferred
into an Eppendorf tube. The solution was centrifuged at 4 °C for
15 min. Commercial enzyme was replaced with an extract con-
taining 30 𝜇g protein in the assay.
2.7.2. Purine Nucleoside Phosphorylase
The effects of quercetin and its metabolites on purine nucleo-
side phosphorylase (PNP) (Geobacterium sp. PNP expressed in Es-
cherichia coli) were tested using both commercial enzyme (Sigma-
Aldrich) and HUVEC extracts using the continuous spectropho-
tometric rate determination procedure. A guanosine analogue,
7-methyl-6-thioguanosine (MESG, Carbosynth Ltd), was used as
the substrate for PNP. Assay buffer containing 50mm potassium
phosphate (pH 7.4) was prepared. It was used to dilute PNP to
0.2 ng 𝜇L−1 and substrate to 800 𝜇m. 50 𝜇L of substrate solution
was added to each well and incubated for 1 min at 37 °C. Reac-
tion was initiated by the addition of 50 𝜇L of enzyme solution.
The increase in absorption at 360 nm was recorded at 30 s inter-
vals for 5 min at 37 °C measuring the formation of the product.
PNP activity was also tested using HUVEC protein extracts. Pro-
cedure involved replacing commercial enzyme in the assay with
HUVEC protein extract containing 30 𝜇g protein.
2.7.3. CD39 and CD73
The effects of quercetin and its metabolites on recombinant
human (rh) ectonucleoside triphosphate diphosphohydrolase-1
(NTPDase, CD39) and 5′nucleotidase (5′-NT, CD73) (R&D
Systems) activities were tested using a colorimetric phosphate
quantification method (Biomol Green Reagent, Enzo Life
Sciences) following the supplier’s assay procedure.
An assay was adapted and optimized from previous
studies[23,24] for testing the effects of quercetin and its con-
jugates on CD39 and CD73 in intact HUVECs. The first step in
the assay involved removing cell culture medium and washing
the cells grown to confluence in 6-well plates three times with the
assay buffer (25 mm Tris, 5 mm CaCl2 for CD39 or 5 mm MgCl2
for CD73, pH 8). This was followed by the incubation of cells
with 2 mL of substrate buffer (assay buffer, 5 mm tetramisole
HCl, 100 𝜇m ATP for CD39 or 50 mm AMP for CD73, pH 8) at
37 °C for 15 min. Ecto-alkaline phosphatase activity was inhib-
ited with the addition of tetramisole HCl. Biomol Green reagent
was used to quantify free phosphate levels. Inhibition studies
involved addition of various concentrations of quercetin and its
conjugates into substrate buffer. Insoluble quercetin conjugates
were dissolved in DMSO (final concentration, 0.1% v/v) prior to
their addition into substrate buffer. Two different sets of blanks
were prepared. The first set contained substrate buffer without
the substrate and quercetin/quercetin conjugates. These were
incubated with the cells. The other set of blanks contained the
substrate buffer containing the substrate without the cells.
2.8. Statistical Analysis
Amix software package (Bruker, Germany) was used to bucket
and integrate water-suppressed NMR spectra. These buckets cov-
ered 0.1–8.9 ppm (4.60–5.0 ppm was omitted due to water sig-
nals). The data matrix of the integrals of these buckets was used
for principal component analysis (PCA) in the multivariate anal-
ysis that was performed using Matlab. Data were scaled to unit
variance to compensate for large differences in intensity among
metabolite signals. Buckets defined in a NMR spectrum repre-
sent a single data point in PCA, and they are responsible for the
separation observed in score and loading plots.
Univariate statistical analyses were performed using Graph-
pad Prism 5.01 software. Non-parametric Mann–Whitney U
test was used to test significant differences between individual
metabolite concentrations. p values less than 0.05 (*p < 0.05,
**p< 0.01, ***p<0.001) were accepted as a significant difference.
3. Results
3.1. Effects of High-Glucose and Quercetin on HUVEC
Metabolites
Of the six different sample preparation methods tested, the op-
timized direct methanol extraction protocol was found to be the
best performing in terms of quenching metabolism and extract-
ing metabolites from cells. Extracted cellular metabolites were
subjected to 1H NMR analysis which facilitated the identification
of 27 intracellular metabolites. Details of the metabolites can be
found in the Supporting Information.
There were three different treatment groups in the ex-
perimental design; normal glucose (5.5 mm glucose for 18
h), high-glucose treated (28.5 mm glucose for 18 h), and
quercetin/glucose treated HUVECs (10 𝜇m quercetin for 2 h
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Figure 1. Multivariate analysis of altered HUVEC metabolic profile. PCA
score plots of 1H NMR data showing separation of normal glucose
(5.5 mm glucose for 18 h), high-glucose (28.5 mm glucose for 18 h), and
quercetin/glucose treated (10 𝜇m quercetin for 2 h followed by 28.5 mm
glucose for 18 h) HUVEC samples (n = 20).
Table 1. Univariate analysis (Mann–Whitney U test) confirmed statistically
significant alterations in the levels of metabolites which contributed to the
separation in multivariate analysis. Metabolite levels in normal glucose
(5.5 mm glucose for 18 h), high-glucose (28.5 mm glucose for 18 h) and
quercetin/glucose (10 𝜇m quercetin for 2 h followed by 28.5 mm glucose
for 18 h) treated HUVECs were compared. ↑, increase; ↓, decrease.
Normal glucose (18 h) vs
High glucose (18 h), n = 38
High glucose (18 h) vs
Quercetin (2 h) /High glucose (18 h), n = 20
Lactate ↑ p < 0.01 Inosine ↑ p < 0.001
Glutamate ↑ p < 0.05 Acetate ↑ p < 0.05
— — Lactate ↓ p < 0.01
— — ATP ↓ p < 0.01
— — NAD+ ↓ p < 0.01
— — Pyruvate ↓ p > 0.05
followed by 28.5 mm glucose for 18 h). A multivariate analysis
showed that the groups were separated on the scores plot of
data indicating alterations in HUVEC metabolic profiles with
different treatments (Figure 1). The metabolites that contributed
significantly to this separation were identified as lactate, ino-
sine, ATP, pyruvate, acetate, glutamate, aspartate, nicotinamide
dinucleotide (NAD+) and asparagine after loading plot analysis.
Furthermore, our univariate analysis (Mann–Whitney U test)
confirmed the significant changes (Table 1).
3.2. Effects of TNF𝜶 and Quercetin on HUVEC Metabolites
There were three different treatment groups in the experimental
design; unstimulated (for 6 h), TNF𝛼 treated cells (10 ng mL−1
TNF𝛼 for 6 h), and quercetin /TNF𝛼 treated (10 𝜇m quercetin
for 2 h followed by10 ng mL−1 TNF𝛼 for 6 h) HUVECs. A mul-
tivariate analysis showed that the groups are separated on the
scores plot of data indicating alterations in HUVEC metabolic
Figure 2. Multivariate analysis of altered HUVEC metabolic profile. PCA
score plots of 1H NMR data showing separation of unstimulated (n = 17),
TNF𝛼 treated (10 ng mL−1 TNF𝛼 for 6 h, n = 17), and quercetin/ TNF𝛼
treated (10 𝜇m quercetin for 2 h followed by 10 ng mL−1 TNF𝛼 for 6 h, n
= 11) HUVEC samples.
Table 2. Univariate analysis (Mann–Whitney U test) confirmed statistically
significant alterations in the levels of metabolites which contributed to
the separation in multivariate analysis. Metabolite levels in unstimulated,
TNF𝛼 treated (10 ng mL−1 TNF𝛼 for 6 h) and quercetin/ TNF𝛼 (10 𝜇m
quercetin for 2 h followed by 10 ng mL−1 TNF𝛼 for 6 h) treated HUVECs
were compared. ↑, increase; ↓, decrease.
Unstimulated (6 h) vs
TNF𝛼 (6 h), n = 17
TNF𝛼 (6 h) vs
Quercetin (2 h) / TNF𝛼 (6 h), n = 11
Asparagine ↑ p < 0.05 Inosine ↑ p = 0.056
Pyroglutamate ↑ p > 0.05 Pyruvate ↓ p < 0.05
Aspartate ↓ p < 0.001 Aspartate ↓ p = 0.057
— — ATP ↓ p > 0.05
profiles with different treatments (Figure 2). The metabolites,
which contributed significantly to this separation, were identified
as pyruvate, NAD+, ATP, inosine, lactate, aspartate, asparagine,
and histidine after loading plot analysis. Furthermore, our uni-
variate analysis (Mann–Whitney test) confirmed the significant
changes (Table 2).
3.3. LC-MS Analysis of Metabolites Involved in Cellular Energy
Metabolism
Having observed that the main treatment-induced alterations
in metabolites occurred in cellular energy metabolism, we
employed what should have been a more sensitive method to
quantify both intra- and extra-cellular concentrations of the
highly polar energy metabolites adenosine, inosine, xanthine,
AMP, ADP, ATP, andNAD+ whichwould showpoor retention on
reversed phase columns. However, AMP, ADP, ATP, and NAD+
could not be detected in extracellularmediumusing thismethod.
High-glucose treatment (28.5 mm, 18 h, n = 6) did not
change intracellular concentrations of any of the metabolites
compared to unstimulated cells (5.5 mm, 18 h, n = 6). However,
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Table 3. LC-MS analysis of changes in HUVEC energy metabolites.
Changes in selected energy metabolites observed with quercetin pre-
treatment before high-glucose (28.5 mm glucose for 18 h) and TNF𝛼
(10 ng mL−1 for 6 h) treatments. ↑, increase; ↓, decrease.
High glucose (18 h) vs
Quercetin (2 h)/High glucose (18 h), n = 6
TNF𝛼 (6 h) vs
Quercetin (2 h)/TNF𝛼 (6 h), n = 6
Intracellular Extracellular Intracellular Extracellular
Inosine* ↑ Inosine** ↑ Inosine*** ↑ Inosine** ↑
ATP** ↓ Xanthine* ↓ Adenosine* ↑ —
ADP* ↓ — — ATP* ↓ —
NAD+** ↓ — — — — —
∗p < 0.05 ∗∗p < 0.01 ∗∗∗p < 0.001
subsequent quercetin treatment caused significant changes in
several metabolites that are shown in Table 3 together with the
changes in metabolites observed after TNF-𝛼 stimulation and
quercetin treatment. Among extracellular metabolites, inosine
was the only one with a significant elevation (p < 0.01).
Furthermore, time-dependent effects of quercetin treatment
on these metabolites were tested. Confluent HUVECs were in-
cubated with 10 𝜇m quercetin for 2, 8, or 20 h, and the changes
in metabolites are shown in Table 4. Among the metabolites
quantified, xanthine was the only intracellular metabolite that
was not affected by the treatments. When the extracellular me-
dia were analyzed, a significant elevation in adenosine concen-
trations (p < 0.01) was observed with 2 h quercetin treatments.
In parallel, a time-dependent elevation was observed in inosine
concentrations. Xanthine concentration was also significantly re-
duced with 20 h quercetin treatment (p < 0.01).
3.4. Fate of Quercetin in the HUVEC Model
Uptake kinetics of quercetin was determined by incubating the
cells with 10 𝜇m quercetin for 2, 8, and 20 h (Figure 3). Quercetin
was metabolized quickly into Q3′-O-S, methylquercetin and 2
other unidentified metabolites. Quercetin and methylquercetin
was detected in intracellular extracts after 2 and 8 h. Q3′-O-S
could not be detected intracellularly at any time point. However,
it could be detected in culture media after 2 h treatment indi-
cating that it was quickly metabolized and removed from the
cells.
Samples containing quercetin, its conjugates and other two
unidentified molecules were analyzed also using LC-MS. The
analysis confirmed the identities of the quercetin, Q3′-O-S and
methylquercetin (details given in the Supporting Information).
Since the retention times of isorhamnetin (3′-OCH3-quercetin)
and tamarixetin (4′-OCH3-methylquercetin) were very similar,
they could not be distinguished. Ultimately, the novelmetabolites
that did not correspond to any of our authentic standards could
not be equivocally identified.However, LC-MS analysis suggested
that they are likely to be dimers of quercetin andmethylquercetin.
3.5. Effects on Enzyme Activities
The inhibitory effects of selected flavonols (2 –70 𝜇m) on activities
of enzymes involved in purine metabolism were tested in both
commercial enzymes and HUVEC extracts, and their IC50 (half
maximal inhibitory concentration) values were calculated where
it was possible (Table 5 and Table 6).
3.5.1. Adenosine Deaminase
Isorhamnetin showed the most potent inhibitory activity which
was followed by quercetin,Q3′-O-S andQ3-O-GlcA. ExceptQ3-O-
GlcA, other conjugates tested showed dose-dependent inhibitory
effects. Nevertheless, Q3-O-GlcA inhibited ADA activity at 2 𝜇m
(p < 0.01, n = 3). The higher concentrations of Q3-O-GlcA did
not affect the residual activity. This prevented us from calculat-
ing IC50 value for the Q3-O-GlcA. The inhibitory activities by
quercetin and its conjugates were similar using both the com-
mercial enzyme and the HUVEC extract. Also, it was shown that
heating the HUVEC extracts to 70 °C halts the enzyme activity
indicating that the loss of adenosine was enzyme dependent.
3.5.2. Xanthine Oxidase
Similarly, isorhamnetin was the most potent inhibitor of xan-
thine oxidase (XO) activity followed by Q3′-O-S, and quercetin.
Xanthine oxidase activity could not be detected in HUVEC
extracts (30–100 𝜇g protein content) although the extracts were
de-salted and concentrated using spin columns (Millipore Micro-
con) in order to prevent any substances interfering with the assay.
Table 4. Alterations in metabolites involved in cellular energy metabolism after 2, 8, and 20 h quercetin (10 𝜇m) challenges (n = 6). Metabolite levels of
unstimulated cells compared to metabolite levels of quercetin treated cells at each time point. Data are presented as the mean ± standard deviation.
2 h 8 h 20 h 2 h 8 h 20 h
Intracellular [%] Extracellular [%]
ATP 180 ± 90 56 ± 16** 71 ± 14** — — —
ADP — — 72 ± 21* — — —
AMP 97 ± 14 154 ± 40* 117 ± 29 — — —
Adenosine 286 ± 19* 73 ± 30 162 ± 65* 113 ± 6** 106 ± 16 103 ± 16
Inosine 122 ± 22 201 ± 41** 273 ± 35** 120 ± 3** 168 ± 4** 303 ± 13**
Xanthine 100 ± 17 103 ± 20 110 ± 13 103 ± 5 104 ± 11 94 ± 1**
NAD+ — 91 ± 10 76 ± 3** — — —
∗p < 0.05. ∗∗p < 0.01. ∗∗∗p < 0.001.
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Figure 3. Uptake andmetabolism of quercetin by HUVECs. A) Changes in
quercetin and its conjugates in culture medium after incubating cells with
10 𝜇m quercetin for 2, 8 and 20 h (n = 3). B) Changes in quercetin and its
conjugates in intracellular fluids of HUVECs after incubating cells with 10
𝜇m quercetin for 2, 8 and 20 h (n = 3). Data are presented as the mean ±
standard deviation according to representative peak integrations of HPLC
chromatograms for quercetin and quercetin conjugates.
3.5.3. Purine Nucleoside Phosphorylase
Bacterial purine nucleosidase activity was inhibited by only
quercetin and Q3′-O-S with IC50 values of 36.9 and 48.3 𝜇m (n
= 3) respectively. The minimum concentrations of quercetin and
Q3′-O-S to inhibit PNP activity significantly were 30 and 15 𝜇m
respectively. Phosphate and sulfate ions were also tested for their
potential inhibitory activities alone or in conjunction with Q3′-
O-S. Nevertheless, these ions did not cause any inhibition in en-
zyme activity by themselves or in conjunctionwithQ3′-O-S. After
the observation of inhibitory activities of quercetin and Q3′-O-S,
they were also tested for their inhibitory effects on PNP activity in
HUVEC extracts. Nevertheless, quercetin aglycone and Q3′-O-S
did not affect PNP activity in HUVEC protein extracts.
3.5.4. CD39
The minimum concentrations of Q3′-O-S, quercetin and Q3′-O-
GlcA to inhibit rhCD39 activity was 2𝜇m (p< 0.001). On the other
hand, quercetin, IsoR3-O-GlcA, and Q3-O-GlcA required mini-
mum15𝜇mconcentration to inhibit rhCD39 activity significantly
(p< 0.05). Quercetin, Q3′-S and isorhamnetin were tested and no
effects were observed in the CD39 activity in intact HUVECs.
3.5.5. CD73
The minimum concentrations of quercetin and isorhamnetin to
inhibit rhCD39 activity significantly were 1 𝜇m (p < 0.01) and
2 𝜇m (p < 0.001) respectively. Only quercetin inhibited CD73 in
intact HUVECs (50 𝜇m, 13% inhibition, n = 3). Isorhamnetin
and Q3′-O-S did not have any inhibitory effects.
4. Discussion
Under physiological conditions, endothelial cells are exposed
to ≈5.5 mm glucose that represents the fasting blood glucose
concentration. This value increases under conditions such as
metabolic syndrome and diabetes in parallel with increases ob-
served in pro-inflammatory cytokine levels.[25,26] In our pre-
liminary experiments, we have assessed the potential of glu-
cose (10–35 mm), TNF𝛼 (0.03–10 ng mL−1) and IL1-𝛽 (0.05–
5 ng mL−1) treatments for different durations on disrupting en-
dothelial cell function and the potential of grape seed extracts
(2.5–10 𝜇g mL−1), resveratrol (0.1–10 𝜇m), resveratrol conjugates
and quercetin (0.1–25 𝜇m) treatments to overcome the deleteri-
ous effects of these aforementioned conditions on endothelial
cell function using approaches targeted on specific endothelial
cell functionmarkers. According to our preliminary unpublished
data, 10 ngmL−1 TNF𝛼 and 10 𝜇m quercetin exerted themost po-
tent disruptive and protective effects respectively. Nevertheless,
glucose did not seem to disrupt endothelial cell function accord-
ing to the results of the targeted experiments. Therefore, the con-
centration and incubation time of glucose used formetabolomics
study were decided based on data obtained from previous studies
where glucose treatments of HUVECs showed pro-inflammatory
effects.[27–29]
In the present study, we have shown that high-glucose concen-
trations and treatment with the pro-inflammatory cytokine TNF𝛼
alter endothelial cell metabolism leading to what would be re-
garded as an unhealthy metabolic phenotype, and show that this
can be ameliorated by treatment with quercetin and its phase-2
metabolites. In our study we have shown that high-glucose
concentrations, TNF𝛼 and quercetin treatments affected mainly
HUVEC energy metabolism. This was obvious with the changes
in intracellular inosine, adenosine, AMP, ADP, ATP, lactate,
pyruvate, NAD+ and amino acids feeding Krebs cycle such as
glutamate, aspartate and asparagine. High-glucose stimulation
increased intracellular lactate and glutamate concentrations
compared to resting cells. Pre-treatment with quercetin prior to
high-glucose stimulation was shown to suppress the increase
in intracellular lactate concentrations. In parallel, increases in
inosine and reductions in ATP concentrations were observed
with quercetin pre-treatment. All these changes are likely to be
associated with the anti-inflammatory properties of quercetin.
Elevated lactate concentrations were observed with high-glucose
treatments since HUVECs preferably use glycolysis for energy
production rather than the Krebs cycle and convert glucose to
lactate even in the presence of oxygen.[30] This phenomenon is
also likely to explain the increase in glutamate concentration
with high-glucose treatment. Glutamate can be converted to
the Krebs cycle intermediate 𝛼-ketoglutarate which feeds into
the Krebs cycle for auxiliary ATP production. Nevertheless,
increased glucose load favors the use of glycolysis limiting
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Table 5. Effects of quercetin and its conjugates on ADA, XO, and PNP activities. Commercial enzymes and HUVEC extracts were used in enzyme assays
to determine IC50 values (n = 3).
Enzyme Inhibitor IC50 [𝜇M] for
commercial enzyme
IC50 [𝜇M] for HUVEC
extract
Adenosine Deaminase Isorhamnetin 48.9 15.7
Quercetin 55.6 20.0
Quercetin 3′-O-Sulfate 195 55.7
Quercetin 3-O-Glucuronide Not calculated Not tested
Xanthine Oxidase Isorhamnetin 0.31 Not tested
Quercetin 3′-O-sulfate 0.45 Not tested
Quercetin 3.0 Not tested
Purine Nucleoside
Phosphorylase
Quercetin 36.9 No inhibition
Quercetin 3′-O-sulfate 48.3 No inhibition
Isorhamnetin No inhibition Not tested
Quercetin 3-O-sulfate No inhibition Not tested
Isorhamnetin 3-O-Glucuronide No inhibition Not tested
Rhamnetin No inhibition Not tested
Quercetin 3′-O-Glucuronide No inhibition Not tested
Quercetin 3-O-Glucuronide No inhibition Not tested
Table 6. Effects of quercetin and its conjugates on enzyme CD39 and CD73 activities. Commercial enzymes and intact HUVECs were used in enzyme
assays to determine IC50 values.
Enzyme Inhibitor IC50 [𝜇M] for
commercial enzyme
IC50 [𝜇M] for HUVEC extract
CD39 Quercetin 3′-O-sulfate 0.18 No inhibition
Quercetin 0.57 No inhibition
Quercetin 3′-O-Glucuronide 10.1 Not tested
Quercetin 3-O-Glucuronide 52.5 Not tested
Isorhamnetin 3-O-Glucuronide 71.2 Not tested
Isorhamnetin No inhibition No inhibition
Tamarixetin No inhibition Not tested
Rhamnetin No inhibition Not tested
CD73 Quercetin 1.7 13% inhibition with 50 𝜇m
quercetin
Isorhamnetin 8.3 No inhibition
Quercetin 3′-O-sulfate 160 No inhibition
Quercetin 3-O-Glucuronide No inhibition Not tested
Isorhamnetin 3-O-Glucuronide No inhibition Not tested
Quercetin 3′-O-Glucuronide No inhibition Not tested
Rutin No inhibition Not tested
the utilization of glutamate. Interestingly, quercetin treatment
repressed lactate concentrations most likely by directing pyru-
vate flux into Krebs cycle.[31] This notion is supported by the
reduction in intracellular NAD+ concentration which indicated
that NAD+ was being reduced into NADH in the Krebs cycle
with quercetin stimulation. In the literature, there are several
studies that reported pro-atherogenic properties of lactate such
as increased reactive oxygen species production (ROS) which in
turn leads to NF-кB activation in HUVECs[32] and increased vas-
cular endothelial cell growth factor (VEGF) and VEGF2 protein
concentrations which in turn increases HUVEC migration and
IL-8 production.[33] Therefore, the reduced lactate concentrations
with quercetin treatments observed in our study are in line with
its anti-atherogenic activity. Beside its anti-atherogenic activity,
reduced lactate concentrations with quercetin treatment demon-
strates also its anti-carcinogenic effects since most cancer cells
prefer to use glycolytic pathway extensively to produce energy
rather than Krebs cycle due to Warburg effect.[34]
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The other changes are observed mainly in purine metabolism
as increases in anti-inflammatorymetabolites inosine and adeno-
sine concentrations together with the reduction in inflammatory
metabolites ATP and ADP. In normal circumstances molecules
like ATP, ADP, AMP and NAD+ are intracellular metabolites.
Identification of any of these metabolites in the culture medium
may indicate leakage of intracellular metabolites into culture
medium during quenching or extraction process.[35] None of
these metabolites were identified neither with 1H NMR nor
MS methods employed in the present study confirming the
quality of the protocol used. Nevertheless ATP can be released
into extracellular environment during inflammation by partic-
ular inflammatory cells,[36] and it was previously shown that
TNF𝛼 induces ATP release by HUVECs.[37] Although it has
been observed that HUVECs release ATP into the extracellular
medium during acute inflammation, we were not able to de-
tect ATP in the extracellular medium. The reason is likely to
be the different incubation times used in the studies. Extracel-
lular ATP was shown to exert its pro-inflammatory activities in
various ways through plasma membrane purinergic receptors.
These include enhancement of production of inflammatory me-
diators such as IL-1, IL-8, monocyte chemoattractant protein-1,
growth regulated oncogene 𝛼 and also activation of cell adhesion
molecules in endothelial cells.[38] Therefore, reductions in intra-
cellular ATP concentrations with quercetin treatments observed
in the present study is important as this limits the amount of
ATP that may leak into extracellular environment after an in-
flammatory stimulus. Similarly, ADP is another potent inflam-
matory metabolite. It can regulate platelet reactivity in vascular
injury sites and show pro-aggregatory activity.[39] However, its
subsequent hydrolysis to AMP and then to adenosine inhibits
platelet aggregation.[39] Therefore, reduction in ADP concentra-
tion with quercetin treatment is another anti-inflammatory pro-
cess observed in the present study.
On the other hand, adenosine is a potent anti-inflammatory
metabolite which acts through G-protein-coupled P1 purinergic
receptor (A2A/2BAR). It has been reported to reduce NF-кB ac-
tivation in various cell types,[40] reduce cell adhesion molecule
expression in endothelial cells[41] and increase basal endothelial
barrier function.[42] Beside its anti-inflammatory effects, adeno-
sine may possess vasodilatory effects. These effects can be ex-
erted through ATP-sensitive K+ (KATP) channels.
[43] Several stud-
ies stated that KATP channels have the potential to function as
metabolic sensors and provide cardioprotective regulations by
coupling cellular metabolism to membrane excitability when the
cells experience disturbances such as hyperglycemia.[44,45] For in-
stance, adenosine was shown to act through A2 adenosine recep-
tors and activate KATP channels.
[43,46] Activated KATP channels al-
low K+ efflux hyperpolarizing the endothelial cells which leads
to Ca2+ influx. Elevated intracellular Ca2+ concentrations were
shown to up-regulate calcium/calmodulin-dependent protein ki-
nase II (CaMKII) in endothelial cells.[47] Subsequent phospho-
rylation of CAMKII leads to activation of endothelial nitric ox-
ide synthase (eNOS) and protein kinase B (Akt) which may in-
crease nitric oxide production that would improve endothelial
cell function. Decreased intracellular ATP and increased intra-
cellular ADP concentrations were also shown to activate KATP
channels.[48] Elevated intra- and extracellular adenosine and de-
creased intracellular ATP concentrations observed in this study
after quercetin treatments bear the potential to activate KATP
channels and exhibit vasodilatory effects. Inosine was another
metabolite reported to reduce inflammatory cytokine produc-
tion showing anti-inflammatory effects both in vitro and in
vivo studies.[49,50] Therefore, adenosine and inosine increases
are also anti-inflammatory processes observed in the present
study.
Energy metabolites such as ATP, ADP and adenosine are ac-
tively involved in cellular signaling cascades, and several polyphe-
nols have been shown to affect the turnover of these metabo-
lites by regulating activities of the enzymes involved in energy
metabolism.[51,52] After investigating metabolism of quercetin in
HUVECs, we explored the effects of quercetin aglycone and its
conjugates on themajor purinemetabolism enzymes which con-
verts ATP into uric acid gradually (Figure 4). In the human body,
quercetin is extensively metabolized into its conjugates after its
consumption.[53] Nevertheless, the biological effects of quercetin
conjugates may not be as consistent as quercetin aglycone,[54]
and there are several in vivo and in vitro studies arguing that
quercetin conjugates, especially glucuronosyl-conjugates,may be
deconjugated at the sites of inflammation by the 𝛽-glucuronidase
activity yielding quercetin aglycone whichmay be responsible for
the biological effects observed.[55,56] Accordingly, we chose to use
quercetin aglycone to treat the cells in the metabolomics part of
the study followed by our study on selected purine metabolism
enzymes in which we also investigated the effects of quercetin
conjugates.
Quercetin and its conjugates were shown to be strong in-
hibitors of rhCD39. However, quercetin and the conjugates
which were identified in the cells and culture medium did not
inhibit CD39 enzymatic activity in the intact HUVECs. This re-
sult is in line with the observation of decreased ATP and ADP
levels after quercetin (20 h) treatments which is most likely due
to increased expression of CD39 protein by HUVECs since a pre-
vious study showed that quercetin increased cellular expression
of CD39.[51]
5′-Nucleotidases can be found either membrane bound (ecto-
5′−-nucleotidase/CD73) or in soluble form in the cells.[57] How-
ever in the present study we have tested our polyphenols only on
CD73 (ecto-5′-nucleotidase) activity since high cellular ATP con-
centrations deactivates soluble 5′-nucleotidase function.[58] The
only flavonol that inhibited CD73 activity in intact HUVECs was
quercetin, and the inhibition was only partial and requiring rela-
tively high quercetin concentrations (50 𝜇m). Nevertheless, the
increased AMP concentration with quercetin treatment in the
present study may be explained by a possible elevation in CD39
protein expression by HUVECs, the minor inhibition of CD73
with quercetin or both. Subsequent demonstration of ADA ac-
tivity inhibition in HUVEC extracts by quercetin, isorhamnetin,
and Q3′-O-S is of importance since we have shown in our study
that quercetin aglycone was absorbed into HUVECs and me-
tabolized into methylquercetin and Q3′-O-S after 2 h quercetin
treatment. Initial studies indicated that ADA activity could be de-
tected only intracellularly.[59] However, more recent studies con-
firmed extracellular ADA activity[60] which together with our data
on ADA inhibition by quercetin aglycone and its conjugates ex-
plained increases in intra- and extracellular adenosine (112.5%
and 286.2% of control levels, respectively) concentrations after
quercetin treatments.
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Figure 4. Purine metabolism pathway. A) The effects of quercetin and selected quercetin conjugates on purine metabolism enzymes. The red arrows
indicate the metabolites whose concentrations were increased and the green arrows indicate the metabolites whose concentrations were decreased after
quercetin treatments (AKA, adenosine kinase, IMP, inosine 5′-monophosphate). Red crosses indicate enzyme inhibition by quercetin or its conjugates.
B) Hypothetical activation of adenosine receptors by increased adenosine concentrations leading to various anti-inflammatory responses.
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It was obvious that inhibition of bacterial PNP is affected by
conjugation of quercetin with methyl or glucuronide groups as
only quercetin and Q3′O-S inhibited the enzyme. Since the com-
petition of sulfate with Pi for the PNP active site was reported
earlier,[61] we have tested the effects of increased sulfate ion and
Pi ion concentrations on bacterial PNP activity and their possible
effects on Q3′-O-S. Neither sulfate nor phosphate ions affected
bacterial PNP activity or the inhibitory activity of Q3′-O-S indi-
cating that inhibitory activity of Q3′-O-S was not due solely to the
conjugated sulfate group. In the light of no inhibition of PNP ac-
tivity in HUVECs with quercetin treatments, the time-dependent
increase in both intra- and extracellular inosine concentrations is
likely to be explained by a possible decrease in the levels of PNP
protein with time after quercetin treatments that might have di-
minished the rate of inosine conversion to hypoxanthine.
There are several studies in the literature which assessed the
effects of various polyphenols including quercetin and its con-
jugates on xanthine oxidase activity.[62,63] In our metabolomics
study, quercetin treatment did not cause any alterations in xan-
thine concentrations indicating that xanthine oxidase activity
might not be affected by quercetin treatments in HUVECs. Nev-
ertheless, we could not confirm that since the enzyme activity in
HUVEC extracts could not be detected with assay used in this
study. Another recent study which also explored the effects of
quercetin and its conjugates on xanthine oxidase, PNP, and ADA
activities found similar results where they could not initially de-
tect xanthine oxidase activity in human plasma and red blood
cells but observed strong inhibition of bovine milk xanthine oxi-
dase activity with quercetin and Q3′O-S. In human plasma, they
did not observe any inhibition of PNP activity with quercetin
which is also in line with the findings in this study where no
inhibition of PNP activity was observed in HUVEC extracts with
quercetin.[64] Nevertheless, they observed only a weak inhibition
of ADA activity in human plasma with quercetin but quercetin
and its conjugates were shown to be potent inhibitors of ADA ac-
tivity in HUVEC extracts in the present study. They emphasized
also the potential role of hemodynamic forces on HUVECs.[64]
Endothelial cells may be affected from hemodynamic forces they
experience during blood flow. HUVECs are naturally exposed to
laminar shear stress in the umbilical cord and the laminar shear
stress is associatedwith athero-protective properties.[65] There are
several studies comparing the effects of laminar shear stress and
oscillatory shear stress on HUVECs.[65,66] However, Tumova and
colleagues compared the expression of selected genes in HU-
VECs grown under static conditions and laminar shear stress.
They revealed increased expression of eNOS, glucose transporter
(GLUT)-3, VEGF, and hemeoxygenase (HO-2) mRNA whereas
ATP binding cassette subfamily B member 1 (ABCB1), ATP
binding cassette subfamily C member 2 (ABCC2), ATP bind-
ing cassette subfamily G member 2 (ABCG2), monocarboxy-
late transporter 1 (MCT1), MCT4, MCT5, 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), organic anion-
transporting polypeptide 4C1(OATP4C1) and GLUT1 mRNA ex-
pression levels were not affected by laminar shear stress.[64] A
potential increase in GLUT3 levels may be relevant to present
study since such a change would allow more glucose in HU-
VECs further elevating gradual lactate concentrations. Neverthe-
less, the rate of glycolysis would not be affected as there were
no changes expected in phosphofructokinase levels, which is the
rate-limiting enzyme in glycolysis. At the same time unaffected
MCT levels would not affect lactate transport from the cells. Sim-
ilarly, transport of hydrophobic molecules and organic anions ap-
peared not be affected as mRNA expression of ABC transporter
genes and OATP4C1 did not change respectively. Therefore, we
may suggest the consideration of potential effects of shear stress
on endothelial cells in future studies.
In conclusion, we have explored the HUVEC metabolite pro-
file and identified and quantified 27 metabolites. Alterations in
HUVEC metabolic profile were demonstrated in response to in-
flammatory conditions and quercetin was shown to ameliorate
some of the glucose-induced changes. The fate of the quercetin
in HUVECs was determined revealing that quercetin enters the
cells and gets metabolized into quercetin conjugates. Quercetin
was shown to alter the balance of HUVEC metabolites towards a
less inflamed phenotype, both alone and in the presence of pro-
inflammatory stimuli. These alterations were shown to be consis-
tent with the inhibition of particular enzymes involved in purine
metabolism by quercetin and its HUVEC metabolites.
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